{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-092586","form_type":"8-K","ticker":"TLSI","cik":"0001826667","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2023-08-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.518441+00:00","generated_at":"2026-06-11T08:44:38.911509+00:00","sec_items":["1.01","2.01","9.01","3.02","4.01","3.03","5.01","5.02","5.03","5.05","5.06","7.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"TriSalus completes de-SPAC merger; FDA asks for additional PERIO-01 dose study","bullets":["Merger closed Aug 10, 2023; MTAC renamed TriSalus Life Sciences, trades on Nasdaq as TLSI and TLSIW.","Gross proceeds ~$42.9M from trust ($2.7M) and PIPE ($40.15M); ~$9.4M redeemed by MTAC stockholders.","Sponsor earnout shares subject to price milestones ($15-$30) over 5 years; lock-up 365 days or $12 trigger.","FDA acknowledged safety of SD-101 with PEDD but requires additional dose-optimization; NDA submission beyond 2025.","Co plans 40-50 patient study for PERIO-01; Phase 2 initiation targeted in 2023 but subject to change."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-092586","json":"https://secwatch.observer/filing/0001104659-23-092586.json","markdown":"https://secwatch.observer/filing/0001104659-23-092586.md","text":"https://secwatch.observer/filing/0001104659-23-092586.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826667/000110465923092586/0001104659-23-092586-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826667/000110465923092586/tm2321991d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T08:44:38.911509+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"008793caf12c726eca047512ffc97c349eecbe67","claim":"TriSalus Life Sciences, Inc.: Approved and adopted a new Code of Business Conduct and Ethics (effective 2023-08-10).","evidence_excerpt":"on August 10, 2023, the New TriSalus Board approved and adopted a new Code of Business Conduct and Ethics applicable to all employees, officers and directors of the Company","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465923092586/0001104659-23-092586-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"code of ethics"},{"label":"Effective","value":"2023-08-10"}],"fact_type":"governance_change"},{"claim_id":"45cdf6bc5705e4f935191b1a675d0a613acad284","claim":"TriSalus Life Sciences, Inc.: Filed Certificate of Incorporation with amendments proposed by Charter Proposal (effective 2023-08-10).","evidence_excerpt":"On August 10, 2023, the Company filed the Certificate of Incorporation with the Delaware Secretary of State","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465923092586/0001104659-23-092586-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-08-10"}],"fact_type":"governance_change"},{"claim_id":"6edb564570e6f8ed66d347db17f5d296d3b68a35","claim":"TriSalus Life Sciences, Inc.: MTAC ceased to be a shell company as a result of the Business Combination (effective 2023-08-10).","evidence_excerpt":"MTAC ceased to be a shell company (as defined in Rule 12b-2 of the Exchange Act) as of the Closing","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465923092586/0001104659-23-092586-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"shell status"},{"label":"Effective","value":"2023-08-10"}],"fact_type":"governance_change"},{"claim_id":"e85233074a7cf6b1f2db12dc1414a53d65f6ea4a","claim":"TriSalus Life Sciences, Inc.: Adopted Amended and Restated Bylaws (effective 2023-08-10).","evidence_excerpt":"also adopted Amended and Restated Bylaws on August 10 , 2023 (the “Bylaws”), which replaced MTAC’s Amended and Restated Certificate of Incorporation and bylaws in effect as of such time","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465923092586/0001104659-23-092586-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2023-08-10"}],"fact_type":"governance_change"},{"claim_id":"4e0edd106a088595baa999e7fe09bc128dd37bca","claim":"TriSalus Life Sciences, Inc. underwent a change of control (closed 2023-08-10).","evidence_excerpt":"As a result of the consummation of the Business Combination, a change of control of MTAC has occurred, and the stockholders of MTAC as of immediately prior to the Closing held 9.7% of the outstanding shares of New TriSalus Common Stock immediately following the Closing.","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465923092586/0001104659-23-092586-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"change of control"},{"label":"Closing","value":"2023-08-10"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}